Roivant Expands Brepocitinib Development Program for Lichen Planopilaris, Announces New Phase 2b/3 Trial, and Reports Batoclimab Phase 3 Study Results for Thyroid Eye Disease

Roivant has expanded its development program for brepocitinib with a new Phase 2b/3 trial in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder. Immunovant's Phase 3 studies of batoclimab in thyroid eye disease (TED) failed to meet their primary endpoint, but showed safety results consistent with previous findings. Roivant will host an investor call to discuss these updates.